1. Accelerating Drugs to Market - Despite Challenges, Adaptive
Clinical Trials Reduce Drug Development Costs and Time to
Market
Report Details:
Published:September 2012
No. of Pages: 63
Price: Single User License – US$3500
GBI Research’s new report, “Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical
Trials Reduce Drug Development Costs and Time to Market”, presents various tools and
strategies which can accelerate a drug to the market. In this report, GBI Research has studied
various hurdles at different stages of drug development that can halt a drug’s development. The
report provides detailed information about the need for accelerated drug development. Declining
R&D productivity is highlighted as one of the major needs to be addressed. The report outlines
misconceptions regarding accelerated drug development; one such major misconception is the
cost of development. The cost of an accelerated development program can be effectively
managed by implementing a structured and complete program. The report highlights major
strategies adopted by pharmaceutical companies to accelerate drug development. The adoption of
the latest technologies in lead generation, preclinical stages, and the use of adaptive designs in
late phase studies are regarded as tools to accelerate drugs through these stages of development.
This report is built using data and information sourced from proprietary databases, primary and
secondary research, and in-house analysis by GBI Research’s team of industry experts.
The process of drug development starts from the initial discovery and ends with a final medication.
This is an expensive, lengthy and incremental process. The main objective of the process is to
identify a molecule with the potential for producing the desired effect in the human body, and to
establish the quality, safety and efficacy of the molecule for treating patients. In the present
scenario drug development takes about 12 years, for a molecule to progress from the laboratory
and enter the pharmaceutical market. It is estimated that out of 5,000 compounds which enter the
preclinical stage of development, only five compounds will be successful enough to be tested on
humans, and only one among them will be approved. The slow pace of drug development greatly
affects the pharmaceutical industry and patients who are in need of new therapeutics to treat their
illness.

2. The current process of drug development begins with the synthesis of molecules, which targets
specific proteins in living cells. It is followed by in vitro tests to identify any specific toxicity
associated with the synthesized molecules. The compounds which make it through this stage will
go further and will be tested for in vivo toxicology studies. The information gathered from these
studies is utilized for planning and conducting clinical trials in human subjects.
It is important for biopharmaceutical companies to launch their products more quickly in the
market, as this will lead to early revenue generation from the product. As a large number of drugs
fail at the later stages of drug development, pharmaceutical companies try to maintain their
revenues by launching new drugs at the earliest possible time. The decline in the total number of
new drug approvals by the regulatory bodies and the patent expirations for major blockbuster
drugs are forcing pharmaceutical companies to consider ways in which the time and cost of clinical
trials can be reduced without affecting their quality.
Scope
•The report presents various tools and strategies which can help to accelerate a drug to market.
•The report provides detailed information about the need for accelerated drug development.
•The report outlines misconceptions regarding accelerated drug development.
•The report provides information on trends in drug transition and strategies and models adopted to
accelerate drug transition through the various stages of development.
•Description of the methods for optimum patient recruitment and retention in a clinical trial.
•Analysis of efficient clinical trial site management so that completion of a trial is done on time.
Reasons to buy
•Develop strategies to implement the use of various technologies for advancing drug discovery
and development in an efficient manner.
•Understand the use of biomarkers and surrogate endpoints, improvised clinical trial designs and
better recruitment and retention of subjects in clinical trials, in order to avoid drug lags in various
phases of development.
•Prioritize design elements of study protocols and balance the overall protocol.
•Ensure efficient clinical trial outcomes by implementing CDISC standards.
•Understand the utility of operationally seamless Phase II/III design for instantaneous transition of
the drug from Phase II to Phase III.
Get your copy of this report @
http://www.reportsnreports.com/reports/192514-accelerating-drugs-to-market-despite-challenges-adaptive-clinical-
trials-reduce-drug-development-costs-and-time-to-market.html
Major points covered in Table of Contents of this report include
Table of Contents
1 Table of Contents 6
1.1 List of Tables 8

3. 1.2 List of Figures 8
2 Introduction 9
3 Accelerating Drugs to Market - Overview 10
3.1 Drug Development Process 12
3.1.1 Early Stage Drug Discovery 12
3.1.2 Clinical Development Time and Protocol Amendments 13
3.1.3 Phase I 14
3.1.4 Phase II 14
3.1.5 Phase III 14
3.1.6 Registration 14
3.1.7 Phase IV 14
3.2 Need to Accelerate the Drug Development Process 15
3.2.1 Strict Regime in Regulations of Drug Approvals 15
3.2.2 Declining Returns on R&D Investment 16
3.2.3 Low R&D Productivity 17
3.3 Misconceptions of Accelerated Drug Development 17
3.3.1 Completeness of the Drug Development Process 17
3.3.2 Cost of Accelerated Drug Development 17
3.3.3 Quality of Study in Accelerated Drug Development 17
3.4 Causes of Delay in Drug Development 18
3.4.1 Delay during the Nonclinical Stage of Drug Development 18
3.4.2 Delay During the Clinical Stage of Drug Development 18
4 Accelerating Drugs Through the Lead Generation Phase 20
4.1 Process of Lead Generation 20
4.1.1 Pre-Discovery 20
4.1.2 Target Identification 21
4.1.3 Target Validation 21
4.1.4 Lead Identification 22
4.1.5 Early Safety Tests 22
4.1.6 Lead Optimization 23
4.2 Traditional Strategies of Lead Generation 24
4.2.1 High Throughput Screening 24
4.2.2 In Vitro Studies of Drug Absorption 25
4.2.3 In Vitro Studies of Protein Binding 25
4.2.4 Fragment-Based Lead Discovery 26
4.2.5 Antisense Technology 27
4.2.6 Iterative Focused Screening 28
4.3 Emerging Strategies of Lead Generation 28
4.3.1 Improving High Throughput Screening 28

4. 4.3.2 Improving In Vitro Assays for HTS 29
4.3.3 Whole Animal Imaging and Microscopy 29
4.3.4 Computerized Combinatorial Chemistry and 3D Molecular Modeling 30
4.3.5 Molecular Bioimaging 32
4.3.6 Omics-Technology and Bioinformatics 33
4.3.7 Outsourcing of Lead Generation 36
5 Accelerating Drugs Through the Preclinical Stage 38
5.1 Preclinical Studies - An Overview 38
5.2 Preclinical Study Design and Planning 38
5.2.1 Preclinical Study - Strategic Planning 38
5.2.2 Key Considerations During Preclinical Study Design 38
5.3 Strategies and Models to Accelerate the Transition from Preclinical Phase to Clinical Phase I
39
5.3.1 In Vitro ADMET Screening Models 40
5.3.2 In Vivo ADMET Screening Models 40
5.3.3 In Silico ADMET Screening Models 41
5.3.4 Accelerating Drugs to Market through Effective Documentation in the Preclinical Phase 41
5.4 Recent Technology Developments 42
5.4.1 Biomarkers 42
5.4.2 Nanotechnology 42
5.4.3 In Vivo Imaging 43
5.5 Accelerating Drugs to Market - Preclinical Models: Case Studies 43
5.5.1 Apredica’s Customized In Vitro ADMET Screening Assays 43
5.5.2 AVEO Pharmaceuticals’ Breakthrough with Transgenic Mouse Model for Human Breast
Cancer 44
5.5.3 Preclinical Models of Hepatocellular Carcinoma and Biomarker Strategy by Pfizer 44
5.5.4 Simulation Modeling to Treat Spinal Cord Injuries by Novartis 45
6 Accelerating Drug Transition in Phase I Studies 46
6.1 Phase I Clinical Studies - An overview 46
6.2 Phase I Study Design and Planning 46
6.2.1 Standard Design 46
6.3 Strategies and Models to Accelerate Transition from Phase I to Phase II 46
6.3.1 Site Selection and Management 46
6.3.2 Strategies to Minimize Site Initiation Delays 48
6.3.3 Role of the Site Management Organization in Decreasing Timelines 49
6.3.4 Optimizing Clinical Trial Supply through a Clinical Trial Management System 50
6.3.5 Patient Recruitment Strategies 51
7 Accelerating Drug Transition in Phase II Studies 53
7.1 Phase II Clinical Studies - An Overview 53

5. 7.2 Phase II Study Design and Planning 53
7.3 Strategies and Models to Accelerate Transition from Phase II to Phase III 53
7.3.1 Selection of Primary Endpoint 53
7.3.2 Randomization of Phase II Trials 53
7.3.3 Use of Biomarkers 54
7.3.4 Statistical Designs in Phase II Trials 54
7.3.5 Increasing Patient Recruitment through the Use of Social Media 54
7.3.6 Seamless Phase II/III Designs 55
8 Accelerating Drug Transition in Phase III Studies 56
8.1 Trends in Drug Transition from Phase III to NDA Filing 56
8.2 Issues and Challenges in Drug Transition 56
8.3 Strategies and Models to Accelerate Transition from Phase III to NDA Filing 56
8.3.1 Adaptive Trial Designs 56
8.3.2 Recruitment and Retention of Patients in Phase III Clinical Trials 57
9 Accelerating Drugs to Market - Appendix 58
9.1 Market Definitions 58
9.2 Abbreviations 58
9.3 Bibliography 59
9.4 Research Methodology 62
9.4.1 Coverage 62
9.4.2 Secondary Research 62
9.4.3 Primary Research 62
9.4.4 Expert Panel Validation 63
9.5 Contact Us 63
9.6 Disclaimer 63
List of Tables
Table 1: Accelerating Drugs to Market, NME Approvals By The FDA, 2004-2011 15
Table 2: Accelerating Drugs to Market, Pharmaceutical and Biotech R&D Expenditure ($bn)
versus Number of NME/BLA Approvals, the US, 2004-2011 16
Table 3: Accelerating Drugs to Market, Comparison of Microdialysis with Ultrafilteration 25
Table 4: Accelerating Drugs to Market, Factors for Minimizing Time Delays in Site Initiation, 2010
48
List of Figures
Figure 1: Accelerating Drugs to Market, Development Timeline for New Drugs 10
Figure 2: Accelerating Drugs to Market, Stages of Drug Development 12
Figure 3: Accelerating Drugs to Market, Amendments per Protocol and Changes per Amendment

6. 13
Figure 4: Accelerating Drugs to Market, NME Approvals By The FDA, 2004-2011 15
Figure 5: Accelerating Drugs to Market, Pharmaceutical and Biotech R&D Expenditure ($bn)
versus Number of NME/BLA Approvals, the US, 2004-2011 16
Figure 6: Lead Generation Strategies and Technologies in Drug Discovery, Drug Discovery
Process 21
Figure 7: Lead Generation Strategies and Technologies in Drug Discovery, Applications of Lead
Generation Process 22
Figure 8: Accelerating Drugs to Market, Pathways For Optimizing Lead Through Screening 23
Figure 9: Lead Generation Strategies and Technologies in Drug Discovery, HTS Absorption,
Distribution, Metabolism and Excretion Assay 24
Figure 10: Lead Generation Strategies and Technologies in Drug Discovery, Evotec’s Approach to
Identifying Novel Beta Secretase-1 Inhibitor Using the Fragment-Based Approach 26
Figure 11: Accelerating Drugs to Market, Benefits And Challenges In Imaging Technique 29
Figure 12: Accelerating Drugs to Market, Service Providers in Combinatorial Chemistry and 3D
Molecular Modeling 31
Figure 13: Accelerating Drugs to Market, Service Providers of Omics Technology and
Bioinformatics 34
Figure 14: Accelerating Drugs to Market, Strategic or Tactical Advantages in Early Stage Drug
Development Outsourcing 36
Figure 15: Accelerating Drugs to Market, Preclinical ADMET Studies - Current System 39
Figure 16: Accelerating Drugs to Market, Site Initiation Process, 2011 47
Figure 17: Accelerating Drugs to Market, Key Factors Responsible for Study Timeline Reduction
by SMOs 49
Figure 18: Accelerating Drugs to Market, Clinical Trial Supply Management System 51
Contact: sales@reportsandreports.com for more information.